BioMark Diagnostics

BioMark Diagnostics CROIC

The Cash Return on Invested Capital (CROIC) of BioMark Diagnostics (BUX.CN) as of Oct 27, 2026 is -330.16 %. In the previous year, Cash Return on Invested Capital (CROIC) was -57.67 % — a change of 472.51% (lower).

CROIC

-330.16 %

YoY

472.51%

Last updated:

Cash Return on Invested Capital (CROIC) of BioMark Diagnostics is 2026 -330.16 % . Cash Return on Invested Capital (CROIC) of BioMark Diagnostics was 2025 -57.67 % . It decreases by 472.51% lower compared to the previous year.

The BioMark Diagnostics CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2019
22.85 CAD
Jan 1, 2020
103.52 CAD
Jan 1, 2021
-2,838.57 CAD
Jan 1, 2022
-1,104.25 CAD
Jan 1, 2023
130.81 CAD
Jan 1, 2024
634.89 CAD
Jan 1, 2025
-57.67 CAD
Jan 1, 2026
-330.16 CAD
The BioMark Diagnostics CROIC history
YEARCROICYoY
-330.16 %+472.51%
-57.67 %-109.08%
634.89 %+385.36%
130.81 %-111.85%
-1,104.25 %-61.10%
-2,838.57 %-2,842.10%
103.52 %+353.01%
22.85 %-73.35%
85.74 %+721.29%
10.44 %-93.98%
173.50 %-123.16%
-749.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioMark Diagnostics Stock analysis

What does BioMark Diagnostics do? BioMark Diagnostics, Inc. generates revenue by developing and commercializing cancer diagnostic solutions designed to detect, monitor, and assess treatment for cancer. The company leverages a molecular diagnostics technology platform that combines metabolomics and machine learning algorithms to enable physicians to detect carcinomas in pre-symptomatic stages. This approach aims to improve cancer prognosis and allows for measuring response to treatment as well as serial monitoring of cancer survivors. The firm focuses on cancers that are difficult to detect and treat by utilizing its liquid biopsy assay to detect Spermidine/spermine N-acetyltransferase 1, an enzyme with elevated levels in numerous cancers. Additionally, the company has developed a high-powered liquid biopsy metabolic panel assay which is instrumental for the early-stage diagnosis of lung cancer. These products serve the medical market by providing advanced tools for early detection and ongoing patient management. BioMark Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioMark Diagnostics stock

Cash Return on Invested Capital (CROIC) of BioMark Diagnostics is -330.16 % in 2026.

Cash Return on Invested Capital (CROIC) of BioMark Diagnostics changed from -57.67 % to -330.16 %, representing a 472.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) BioMark Diagnostics since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s BioMark Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — BioMark Diagnostics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — BioMark Diagnostics